Natixis Advisors LLC Has $101.15 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Key Points

• Natixis Advisors LLC increased its stake in Amgen Inc. by 15.3%, acquiring an additional 43,086 shares during the first quarter, bringing its total holdings to approximately $101.1 million.
• Institutional investors collectively own 76.50% of Amgen's stock, with several firms, including NorthRock Partners and Tower Bridge Advisors, also increasing their positions in the company.
• Amgen reported a 9.4% increase in quarterly revenue year-over-year, achieving earnings per share of $4.90, which exceeded analysts' expectations by $0.72.

Natixis Advisors LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 15.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 324,653 shares of the medical research company's stock after acquiring an additional 43,086 shares during the period. Natixis Advisors LLC owned 0.06% of Amgen worth $101,146,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. NorthRock Partners LLC grew its position in shares of Amgen by 7.6% during the first quarter. NorthRock Partners LLC now owns 11,071 shares of the medical research company's stock worth $3,449,000 after acquiring an additional 780 shares during the last quarter. Tower Bridge Advisors grew its position in Amgen by 3.2% in the 1st quarter. Tower Bridge Advisors now owns 13,909 shares of the medical research company's stock valued at $4,333,000 after buying an additional 430 shares in the last quarter. Wellington Shields & Co. LLC grew its position in Amgen by 7.2% in the 1st quarter. Wellington Shields & Co. LLC now owns 5,159 shares of the medical research company's stock valued at $1,607,000 after buying an additional 345 shares in the last quarter. Woodley Farra Manion Portfolio Management Inc. grew its position in Amgen by 2.0% in the 1st quarter. Woodley Farra Manion Portfolio Management Inc. now owns 14,406 shares of the medical research company's stock valued at $4,488,000 after buying an additional 280 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. grew its position in Amgen by 0.9% in the 1st quarter. Mesirow Financial Investment Management Inc. now owns 14,214 shares of the medical research company's stock valued at $4,429,000 after buying an additional 127 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president owned 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.76% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. William Blair reiterated an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. Wall Street Zen upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. UBS Group increased their target price on shares of Amgen from $315.00 to $326.00 and gave the company a "neutral" rating in a research report on Monday, July 21st. Piper Sandler reiterated an "overweight" rating and issued a $328.00 target price on shares of Amgen in a research report on Friday, June 27th. Finally, Erste Group Bank downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $307.27.

Amgen Trading Up 0.6%

AMGN stock traded up $1.78 during mid-day trading on Friday, reaching $296.88. 2,410,860 shares of the stock traded hands, compared to its average volume of 1,708,073. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $339.17. The company has a market cap of $159.64 billion, a P/E ratio of 27.09, a P/E/G ratio of 2.55 and a beta of 0.49. The stock's fifty day moving average is $292.04 and its 200-day moving average is $291.87.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The firm's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.96 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 22nd will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2%. Amgen's dividend payout ratio is 86.86%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.